NCT00989612View on ClinicalTrials.gov

Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 1, 2009

Primary Completion Date

April 19, 2010

Study Completion Date

April 19, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza investigational vaccine GSK2340274A

Two intramuscular injections on Day 0 and Day 21, respectively

Trial Locations (2)

813-8588

GSK Investigational Site, Fukuoka

204-8585

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00989612 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) | Biotech Hunter | Biotech Hunter